Analysts Are Betting On Cellectis S.A. (EPA:ALCLS) With A Big Upgrade This Week

Shareholders in Cellectis S.A. (EPA:ALCLS) may be thrilled to learn that the analysts have just delivered a major upgrade to their near-term forecasts. The revenue forecast for next year has experienced a facelift, with analysts now much more optimistic on its sales pipeline. The market seems to be pricing in some improvement in the business too, with the stock up 9.8% over the past week, closing at €24.70. It will be interesting to see if this latest upgrade is enough to kickstart further buying interest in the stock.

Following the upgrade, the most recent consensus for Cellectis from its eight analysts is for revenues of US$89m in 2021 which, if met, would be a huge 22% increase on its sales over the past 12 months. Prior to the latest estimates, the analysts were forecasting revenues of US$80m in 2021. It looks like there's been a clear increase in optimism around Cellectis, given the nice gain to revenue forecasts.

See our latest analysis for Cellectis

Additionally, the consensus price target for Cellectis increased 42% to €29.20, showing a clear increase in optimism from the analysts involved.

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. For example, we noticed that Cellectis' rate of growth is expected to accelerate meaningfully, with revenues forecast to grow 22%, well above its historical decline of 8.1% a year over the past five years. Compare this against analyst estimates for the wider industry, which suggest that (in aggregate) industry revenues are expected to grow 25% next year. So it looks like Cellectis is expected to grow at about the same rate as the wider industry.

The Bottom Line

The highlight for us was that analysts increased their revenue forecasts for Cellectis next year. They're also forecasting for revenues to grow at about the same rate as companies in the wider market. There was also a nice increase in the price target, with analysts apparently feeling that the intrinsic value of the business is improving. Seeing the dramatic upgrade to next year's forecasts, it might be time to take another look at Cellectis.

Looking for more information? At least one of Cellectis' eight analysts has provided estimates out to 2024, which can be seen for free on our platform here.

Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are upgrading their estimates. So you may also wish to search this free list of stocks that insiders are buying.

When trading Cellectis or any other investment, use the platform considered by many to be the Professional's Gateway to the Worlds Market, Interactive Brokers. You get the lowest-cost* trading on stocks, options, futures, forex, bonds and funds worldwide from a single integrated account. Promoted

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
^*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.